Purpose We investigated the combination of lymphodepleting chemotherapy followed by the
Purpose We investigated the combination of lymphodepleting chemotherapy followed by the adoptive transfer of autologous tumor reactive lymphocytes for the treatment of patients with refractory metastatic melanoma. mediate significant tumor regression in heavily pretreated patients with Semaxinib manufacturer IL-2 refractory metastatic melanoma. INTRODUCTION Adoptive cell transfer (ACT) immunotherapy is based on the ex vivo selection … [Read more…]